Topic: Biovail Corporation
Valeant Pharmaceuticals (NYSE: VRX)'s stock had its "buy" rating reaffirmed by equities research analysts at Jefferies Group (NYSE: JEF) in a...
Thesis. . Intellipharmaceutics (IPCI) represents an unusual deep value opportunity with respect to the net present value of its businesses as...
Posted on 09/07/11 at 8:31am by Abe Raymond . Cornerstone Therapeutics Inc. (NASDAQ: CRTX ), a specialty pharmaceutical company focused on...
Equities research analysts at Goldman Sachs (NYSE: GS) initiated coverage on shares of Valeant Pharmaceuticals (NYSE: VRX) in a research note to...
Equities research analysts at Piper Jaffray (NYSE: PJC) boosted their price target on shares of Valeant Pharmaceuticals (NYSE: VRX) from $46.00 to...
Valeant's (VRX) management team no doubt means what it says when it calls for a swift resolution to its surprise bid for Cephalon (CEPH). By making...
Posted on 02/08/11 at 8:09am by Benzinga Staff . Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) today announced that its subsidiary...
Dr. Isa Odidi of Intellipharmaceutics (IPCI) is easily one of the sector's genius drug delivery innovators. While he was at Biovail (BVF), Odidi...
Following Alexza's (ALXA) meeting with the U.S. FDA relating to the complete response letter (CRL) in October 2010 for AZ-004 (Staccato loxapine)...
Equities research analysts at Ladenburg Thalmann boosted their price target on shares of Valeant Pharmaceuticals (NYSE: VRX) from $33.00 to $50.00...